American pharmaceutical company Eli Lilly plans to build a $3bn manufacturing facility at the Leiden Bio Science Park in Katwijk, the Netherlands.
It will have advanced technologies for making oral solid medicines for use in cardiometabolic health, neuroscience, oncology and immunology.
Techniques used include dock-to-dock automation and material flow, paperless manufacturing, process analytical technology and spray-dried dispersion, allowing for oral medicines to be effectively absorbed.
Construction on the project will create 1,500 jobs, with 500 engineering, science and operational jobs available when completed.
David A. Ricks, Eli Lilly’s chief executive, said: “With extensive investments already underway in the US, our planned expansion in Europe further strengthens our ability to deliver medicines to patients worldwide.
“Localised manufacturing ensures we can quickly respond to meet regional demand and accelerate distribution within Europe.”
Construction is due to begin in 2026 and is still subject to conditions.
- Subscribe here to get stories about construction around the world in your inbox three times a week
Further Reading:
